Recombinant human growth hormone (r-hGH)

DRUG3 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

Dwarfism, PituitaryHypochondroplasiaInfant, Small for Gestational Age

Phase 2

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

CompletedNCT01111019

Merck KGaA, Darmstadt, GermanyHypochondroplasia

Start: 2006-03-21End: 2017-01-17Updated: 2019-02-15

Phase 3

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

TerminatedNCT01067352

Merck KGaA, Darmstadt, GermanyInfant, Small for Gestational Age

Start: 2004-02-29End: 2009-07-31Updated: 2013-12-27

Phase 4

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

CompletedNCT01187550

Merck KGaA, Darmstadt, GermanyDwarfism, Pituitary

Start: 2007-03-31End: 2009-04-30Updated: 2014-02-13

Related Papers

Comparative evaluation of short-term biomarker response to treatment for growth hormone deficiency in Chinese children with growth hormone deficiency born small for or appropriate for gestational age: a randomized phase IV open-label study.

2013-04-016 citations